uniQure submits biologics license application for ifezuntirgene inilparvovec in Huntington’s
uniQure (QURE) announced submission of a Biologics License Application for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease.
Story updates
11:07:26 AM UTC
SquawkNews
~ Company also announces the submission of a Marketing Authorisation Application for ifezuntirgene inilparvovec in the U.K. ~~ Both submissions are supported by the three-year data analysis from the Phase I/II study, in which ifezuntirgene inilparvovec demonstrated a slowing of disease progression…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.